Watch Galapagos CEO Onno van de Stolpe discuss the transformational multi-billion dollar collaboration with Gilead
Galapagos NV in collaboration with Gilead to create a global R&D leader based in Europe
Galapagos NV in collaboration with Gilead to create a global R&D leader based in Europe
Optimum’s 11th Annual Healthcare Investor Conference 2019 at Bloomberg. Pop it in the diary now!
“New technologies like RNA inhibitors that alter the genetic drivers of a disease, have the potential to transform medicine…”
Listen to Ixico’s interview on Vox Market’s daily podcast with Justin Waite. Forward to 23:00 minutes to hear them discuss their growth…
Niall Martin is on a mission to put DNA repair on the map. He has already gone pretty far along the way to doing this, as the leader of the … Continue reading “Artios Pharma CEO, Niall Martin is on a mission to put DNA repair on the map”
Click this link to register and listen to the insightful podcast from Verona Pharma’s Investor and Analyst R&D Day forum 2019
Continuing Cambridge’s tradition as a centre of excellence for DNA Damage Response with leading next generation programmes.
Arix Bioscience (ARIX) CEO Joe Anderson talked to VoxMarkets about investing in and building breakthrough biotech companies to market.
Only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK
Stephan Christgau, Senior Partner
Novo Seeds.
Nomination deadline 11th April 2019
John Cassidy
Investment Associate
Arix Bioscience plc
Robert James
Managing Partner
Sixth Element Capital
Will this trend continue? Analysis of Biopharma M&A in 2018 (and previous years)
Since 2011, over 40 European healthcare start-ups have used equity crowdfunding, rather than the traditional venture capital (VC) route…
New advances in technology are having a tremendous impact through the entire healthcare spectrum.
Dr Niall Kirk profiles this alternative source of capital while introducing readers to the online crowdfunding marketplace
Designed to help high-potential businesses understand the role of capital markets and how they can reach the next stage of their growth.
Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com